These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33412597)

  • 1. The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies.
    Grosso G; Sandholm K; Antovic A; Gunnarsson I; Zickert A; Vikerfors A; Truedsson L; Bruzelius M; Nilsson B; Nilsson-Ekdahl K; Svenungsson E
    Thromb Haemost; 2021 Oct; 121(10):1299-1309. PubMed ID: 33412597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
    Front Immunol; 2019; 10():885. PubMed ID: 31134052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.
    Lonati PA; Scavone M; Gerosa M; Borghi MO; Pregnolato F; Curreli D; Podda G; Femia EA; Barcellini W; Cattaneo M; Tedesco F; Meroni PL
    Front Immunol; 2019; 10():773. PubMed ID: 31031764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.
    Hisada R; Kato M; Sugawara E; Kanda M; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
    J Thromb Haemost; 2019 Jul; 17(7):1134-1143. PubMed ID: 30864219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered β
    Mobarrez F; Gunnarsson I; Svenungsson E
    J Thromb Haemost; 2017 Sep; 15(9):1799-1806. PubMed ID: 28667788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus.
    Garabet L; Gilboe IM; Mowinckel MC; Jacobsen AF; Mollnes TE; Sandset PM; Jacobsen EM
    Scand J Immunol; 2016 Aug; 84(2):95-9. PubMed ID: 27135178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.
    Idborg H; Zandian A; Sandberg AS; Nilsson B; Elvin K; Truedsson L; Sohrabian A; Rönnelid J; Mo J; Grosso G; Kvarnström M; Gunnarsson I; Lehtiö J; Nilsson P; Svenungsson E; Jakobsson PJ
    Arthritis Res Ther; 2019 Feb; 21(1):62. PubMed ID: 30777133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological evolution in women with positive antiphospholipid antibodies.
    Riancho-Zarrabeitia L; Daroca G; Muñoz P; López-Hoyos M; Haya A; Martínez-Taboada VM
    Semin Arthritis Rheum; 2017 Dec; 47(3):397-402. PubMed ID: 28576307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome.
    Breen KA; Seed P; Parmar K; Moore GW; Stuart-Smith SE; Hunt BJ
    Thromb Haemost; 2012 Mar; 107(3):423-9. PubMed ID: 22234447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus.
    Goldstein R; Moulds JM; Smith CD; Sengar DP
    J Rheumatol; 1996 Jul; 23(7):1173-9. PubMed ID: 8823688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.
    Peerschke EI; Yin W; Alpert DR; Roubey RA; Salmon JE; Ghebrehiwet B
    Lupus; 2009 May; 18(6):530-8. PubMed ID: 19395455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.
    Unlu O; Erkan D; Barbhaiya M; Andrade D; Nascimento I; Rosa R; Banzato A; Pengo V; Ugarte A; Gerosa M; Ji L; Efthymiou M; Branch DW; de Jesus GR; Tincani A; Belmont HM; Fortin PR; Petri M; Rodriguez E; Pons-Estel GJ; Knight JS; Atsumi T; Willis R; Zuily S; Tektonidou MG;
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):134-141. PubMed ID: 29669399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients.
    Kozora E; Erkan D; Zhang L; Zimmerman R; Ramon G; Ulug AM; Lockshin MD
    Clin Exp Rheumatol; 2014; 32(1):34-40. PubMed ID: 24021640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus.
    Lood C; Tydén H; Gullstrand B; Sturfelt G; Jönsen A; Truedsson L; Bengtsson AA
    PLoS One; 2014; 9(6):e99386. PubMed ID: 24922069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive.
    Giles I; Rahman A
    Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):525-37. PubMed ID: 19591782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
    Fischer K; Brzosko M; Walecka A; Ostanek L; Sawicki M
    Pol Arch Med Wewn; 2007; 117 Suppl():13-7. PubMed ID: 18778013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.